 |
Source = Classys |
[Alpha Biz= Paul Lee] Classys is expected to post around 30% growth this year, driven by its acquisition of a Brazilian distributor and expanding global sales, Sangsangin Securities said on March 11.
Analyst Ha Tae-ki projected that the company’s 2025 consolidated revenue will reach 451 billion won, up 33% year-on-year, while operating profit is expected to rise 24.6% to 212.6 billion won.
First-quarter revenue is estimated at 88 billion won, up 14.1% from a year earlier, with operating profit projected to increase 13.4% to 44 billion won. Ha said the relatively modest growth reflects the fact that the acquisition of Brazilian aesthetic medical device distributor Medsystems, completed in early March, contributed to earnings for only about one month in the quarter.
Sales of existing devices and consumables are also expected to grow this year. The analyst said the company’s portfolio is expanding with new products such as QuadSay and RePot, alongside existing devices Shurink and Volnewmer.
Regionally, Europe and North America are expected to drive equipment sales growth. Volnewmer was launched in the U.S. market at the end of 2024, while QuadSay is scheduled for U.S. release in the first quarter of 2026. In Europe, sales are expected to increase on the back of regulatory approvals for Ultraformer MPT and Volnewmer.
Ha highlighted the Brazilian market expansion as a key growth driver, estimating that the Medsystems acquisition could generate about 50 billion won in additional revenue this year.
While the company’s earnings outlook remains strong, he noted that potential share sales by major shareholders and valuation concerns in the sector could keep the stock moving within a trading range, suggesting a strategy of buying near the lower end of the range and selling near the upper end.
Alphabiz Reporter Paul Lee(hoondork1977@alphabiz.co.kr)
